Description
Global Digital PCR Market Industry Overview
The global digital PCR market is projected to reach $2,847.8 million by 2032 from $441.2 million in 2021, at a CAGR of 18.73% during the forecast period 2022-2032. The growth in the global digital PCR market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases globally, the rising awareness of d-PCR-based diagnostic testing, and the significant number of funding for executing research and development.
Market Lifecycle Stage
The global digital PCR market is progressing rapidly with a significant increase in research and development (R&D) activities pertaining to a wide range of d-PCR products for disease detection, accentuating their criticality in healthcare. Digital PCR has a critical role in the molecular diagnostics approach, as it ensures the safe and effective application of disease diagnosis. Most players in the global digital PCR market offer products, such as kits and assays, systems, and reagents and consumables.
Increasing investments in R&D for d-PCR molecular diagnostics is one of the major opportunities in the global digital PCR market. Several biotechnology and life sciences companies are working collaboratively on diagnostic test development and using d-PCR as a therapeutic means for applications in several disease indications to enable efficient diagnosis, treatment selection, and treatment monitoring.
Impact of COVID-19
The current global digital PCR market comprises kits and assays, system, and reagents and consumables. The unexpected crisis of the pandemic has surged the demand for essentials and increased the demand for digital PCR products. There was increased demand for digital PCR from biotechnology and life sciences companies. Overall, the impact of COVID-19 on the global d-PCR market size has been low-moderate. Some market players have reported a slight decline in sales. However, some new entrants in the global d-PCR market are expected to witness growth in the market. There is also a decline in revenues mostly due to the initial phases of the COVID-19 pandemic, which comprised complete lockdowns across countries and major cities, thereby interrupting the supply chain. Several other products have been under development for years that may take longer than 2-4 years for commercialization. The pandemic has played a key role in enhancing the growth prospects of digital PCR-based diagnostics and is expected to indirectly aid in improving the market growth outlook.
Market Segmentation:
Segmentation 1: by Product
• Kits and Assays
• Systems
• Reagents and Consumables
The global digital PCR market based on the product segment was dominated by kits and assays in 2021. This is due to an increasing number of research institutes involved in carrying out in vitro diagnostic (IVD) tests in the field of d-PCR-based diagnosis.
Segmentation 2: by Application
• Oncology
• Infectious Diseases
• Rare Diseases
• Gene Expression
• Reproductive Genetics
• Other Applications
In 2021, oncology dominated the application segment of the global digital PCR market.
Segmentation 3: by End User
• Academic and Research Institutions
• Biopharmaceutical Companies
• Diagnostic Centers
• Hospitals and Clinics
The academic and research institutions dominated the end-user segment in the global d-PCR market in 2021, as research laboratories, particularly, are most involved in carrying out research studies focused on identifying and understanding the diagnostic application of digital PCR.
Recent Developments in the Global Digital PCR Market
• In March 2022, Stilla signed an agreement with 12 distributors throughout EMEA. This agreement grants distribution rights to Stilla’s full product portfolio, including the six-color naica system.
• In April 2022, Stilla and Promega Corporation signed a co-marketing agreement to offer a complete digital PCR workflow solution to provide their end users with optimized workflow for a wide range of applications, including liquid biopsy, sentinel pathogen testing, infectious disease assay, overall cancer research, and drug discovery.
• In October 2021, Bio-Rad Laboratories, Inc. acquired Dropworks, Inc., a development stage company focused on developing a digital PCR product. The strategy was to increase and complement the company’s life sciences product offerings.
• In September 2021, Thermo Fisher Scientific launched the Applied Biosystems QuantStudio Absolute Q Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results.
Demand – Drivers and Limitations
Following are the demand drivers for the global digital PCR market:
• Technological Transformations Related to Digital PCR
• Rising Adoption of Digital PCR among Various Applications
• Increasing Activities in d-PCR Ecosystem
The market is expected to face some limitations too due to the following challenges:
• Higher Cost of Droplet Digital PCR
• Presence of Opaque Regulatory Framework
How can this report add value to an organization?
Growth/Marketing Strategy: Owing to the explosion of massively parallel sequencing and its applications, all areas of healthcare have been affected, particularly PCR-based molecular diagnostics. The key components in the digital PCR market consist of a diverse range of d-PCR-based products, generally purchased by the testing companies and the testing services themselves. The entire workflow is well explained in the report, along with pricing analysis considering the applications used in testing.
Competitive Strategy: Key players in the global d-PCR market analyzed and profiled profiled in the study, consisting of both products-based companies and a few emerging companies. Moreover, a detailed competitive benchmarking of the players operating in the global digital PCR market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are:
• Bio-Rad Laboratories, Inc.
• Fluidigm Corporation
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
• Genetron Holdings Limited
• JN Medsys
• Stilla
• Naveris, Inc.
• SAGA Diagnostics
Table of Contents
1 Markets
1.1 Product Definition
1.1.1 Inclusion and Exclusion
1.2 Market Scope
1.2.1 Scope of Work
1.2.2 Key Questions Answered in the Report
2 Research Methodology
2.1 Global Digital PCR Market: Research Methodology
2.2 Data Sources
2.2.1 Primary Data Sources
2.2.2 Secondary Data Sources
2.3 Market Estimation Model
2.4 Criteria for Company Profiling
3 Market Overview
3.1 Market Definition
3.2 d-PCR vs. qPCR
3.3 Market Footprint and Growth Potential
3.4 COVID-19 Impact on the Global Digital PCR Market
3.4.1 Impact on Research and Clinical Operations
3.4.2 Impact on Market Players
3.4.3 Impact on Market Growth
4 Industry Analysis
4.1 Overview
4.1.1 Regulatory Framework in the U.S.
4.1.2 Regulatory Framework in European Union (EU)
4.1.3 Regulatory Framework in Asia-Pacific
4.1.3.1 Japan
4.1.3.2 China
4.2 Patent Analysis
4.2.1 Patent Analysis (by Region)
4.2.2 Patent Analysis (by Country)
4.2.3 Patent Analysis (by Year)
5 Market Dynamics
5.1 Overview
5.2 Impact Analysis
5.2.1 Market Drivers
5.2.1.1 Technological Transformations Related to Digital PCR
5.2.1.2 Rising Adoption of Digital PCR among Various Applications
5.2.1.3 Increasing Activities in d-PCR Ecosystem
5.2.2 Market Restraints
5.2.2.1 Higher Cost of Droplet Digital PCR
5.2.2.2 Presence of Opaque Regulatory Framework
5.2.3 Market Opportunities
5.2.3.1 Extensive Adoption of Genetic Testing, especially in Developing Nations
5.2.3.2 Increasing Adoption of d-PCR in Chronic Disease Diagnosis
6 Competitive Landscape
6.1 Competitive Landscape
6.1.1 Mergers and Acquisitions
6.1.2 Synergistic Activities
6.1.3 Product Launch and Approval Activities
6.1.4 Expansion, Funding, and Other Activities
6.1.5 Market-Share Analysis
6.1.6 Growth-Share Analysis
6.1.6.1 Growth-Share Analysis (by Company)
6.1.6.2 Growth-Share Analysis (by Application Type)
6.2 Supply Chain Analysis
7 Product
7.1 Overview
7.1.1 Systems
7.1.1.1 Droplet Digital PCR Systems
7.1.1.2 Chip-Based Digital PCR Systems
7.1.2 Kits and Assays
7.1.2.1 Droplet Digital PCR Systems
7.1.2.2 Chip-Based Digital PCR
7.1.3 Reagents and Consumables
7.1.3.1 Droplet Digital PCR
7.1.3.2 Chip-Based Digital PCR
8 Application Type
8.1 Overview
8.1.1 Oncology
8.1.1.1 Solid Tumor
8.1.1.2 Hematological Malignancies
8.1.2 Infectious Diseases
8.1.2.1 Respiratory Infections
8.1.2.2 Gastrointestinal Infections
8.1.2.3 Other Infectious Diseases
8.1.3 Rare Diseases
8.1.3.1 Inherited Trait Type
8.1.3.2 Acquired Trait Type
8.1.4 Reproductive Genetics
8.1.4.1 Prenatal Diseases
8.1.4.2 Postnatal Diseases
8.1.5 Gene Expression
8.1.6 Other Applications
9 End User
9.1 Overview
9.1.1 Academic and Research Institutions
9.1.2 Hospitals and Clinics
9.1.3 Diagnostic Centers
9.1.4 Biopharmaceutical Companies
10 Region
10.1 Overview
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 France
10.3.3 U.K.
10.3.4 Italy
10.3.5 Spain
10.3.6 Rest-of-Europe
10.4 Asia-Pacific
10.4.1 Japan
10.4.2 China
10.4.3 Australia
10.4.4 South Korea
10.4.5 Rest of Asia-Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest-of-Latin America
10.6 Rest-of-the-World (RoW)
10.6.1 Middle East
10.6.1.1 K.S.A.
10.6.1.2 Egypt
10.6.1.3 Rest-of-Middle East
10.6.2 Africa
11 Company Profiles
11.1 Overview
11.2 Bio-Rad Laboratories, Inc.
11.2.1 Company Overview
11.2.2 Role of Bio-Rad Laboratories, Inc. in the Global Digital PCR Market
11.2.3 Key Competitors of the Company
11.2.4 Key Customers of the Company
11.2.5 Synergistic Activities
11.2.6 Business Strategies
11.2.6.1 Product Launch/Approval
11.2.7 Financials
11.2.8 Analyst Perspective
11.3 Fluidigm Corporation
11.3.1 Company Overview
11.3.2 Role of Fluidigm Corporation in the Global d- PCR Market
11.3.3 Key Competitors of the Company
11.3.4 Key Customers of the Company
11.3.5 Corporate Strategies
11.3.5.1 Synergistic Activities
11.3.6 Financials
11.3.7 Analyst Perspective
11.4 F. Hoffmann-La Roche Ltd.
11.4.1 Company Overview
11.4.2 Role of F. Hoffmann-La Roche Ltd. in the Global d-PCR Market
11.4.3 Key Competitors of the Company
11.4.4 Corporate Strategies
11.4.4.1 Synergistic Activities
11.4.5 Financials
11.4.6 Analyst Perspective
11.5 Merck KGaA
11.5.1 Company Overview
11.5.2 Role of Merck KGaA in the Global Digital PCR Market
11.5.3 Key Competitors of the Company
11.5.4 Financials
11.5.5 Analyst Perspective
11.6 QIAGEN N.V.
11.6.1 Company Overview
11.6.2 Role of QIAGEN N.V. in the Global Digital PCR Market
11.6.3 Key Competitors of the Company
11.6.4 Corporate strategies
11.6.4.1 Synergistic Activities
11.6.5 Business Strategies
11.6.5.1 Product Launch/Approval
11.6.6 Financials
11.6.7 Analyst Perspective
11.7 Thermo Fisher Scientific Inc.
11.7.1 Company Overview
11.7.2 Role of Thermo Fisher Scientific Inc. in the Global Digital PCR Market
11.7.3 Key Competitors of the Company
11.7.4 Corporate strategies
11.7.4.1 Synergistic Activities
11.7.5 Business Strategies
11.7.5.1 Product Launch/Approval
11.7.6 Financials
11.7.7 Analyst Perspective
11.8 Genetron Holdings Limited
11.8.1 Company Overview
11.8.2 Role of Genetron Holdings Limited in the Global Digital PCR Market
11.8.3 Key Competitors of the Company
11.8.4 Key Customers of the Company
11.8.5 Corporate Strategies
11.8.5.1 Synergistic Activities
11.8.6 Financials
11.8.7 Analyst Perspective
11.9 JN Medsys
11.9.1 Company Overview
11.9.2 Role of JN Medsys in the Global Digital PCR Market
11.9.3 Key Competitors of the Company
11.9.4 Analyst Perspective
11.1 Stilla
11.10.1 Company Overview
11.10.2 Role of Stilla in the Global Digital PCR Market
11.10.3 Key Competitors of the Company
11.10.4 Corporate Strategies
11.10.4.1 Synergistic Activities
11.10.5 Business Strategies
11.10.5.1 Product Launch/Approval
11.10.6 Analyst Perspective
11.11 Naveris, Inc.
11.11.1 Company Overview
11.11.2 Role of Naveris, Inc. in the Global Digital PCR Market
11.11.3 Key Competitors of the Company
11.11.4 Corporate strategies
11.11.4.1 Synergistic Activities
11.11.5 Analyst Perspective
11.12 SAGA Diagnostics
11.12.1 Company Overview
11.12.2 Role of SAGA Diagnostics in the Global Digital PCR Market
11.12.3 Key Competitors of the Company
11.12.4 Corporate strategies
11.12.4.1 Synergistic Activities
11.12.5 Analyst Perspective
11.13 Emerging Companies
11.13.1 Precigenome LLC
11.13.2 RevoSketch Inc.
List of Figures
Figure 1: Global Digital PCR Market (by Product), $Million, 2021 and 2032
Figure 2: Global Digital PCR Market (by Application Type), $Million, 2021 and 2032
Figure 3: Global Digital PCR Market (by Region), $Million, 2021 and 2032
Figure 4: Global Digital PCR Market (by End User), $Million, 2021 and 2032
Figure 5: Global Digital PCR Market Segmentation
Figure 6: Global Digital PCR Market: Research Methodology
Figure 7: Primary Research Methodology
Figure 8: Bottom-Up Approach (Segment-Wise Analysis)
Figure 9: Top-Down Approach (Segment-Wise Analysis)
Figure 10: Evolution of Digital PCR
Figure 11: Global Digital PCR Market, $Million, 2021-2032
Figure 12: Pre-COVID-19 and Post-COVID-19 Scenario of Global Digital PCR Market, $Million, 2019-2025
Figure 13: Components Considered for Clinical Actionability as per the IVDR
Figure 14: Region-Wise Analysis of Patents, January 2020-July 2022
Figure 15: Country-Wise Analysis of Patents, January 2020-July 2022
Figure 16: Year-Wise Analysis of Patents, January 2020-July 2022
Figure 17: Global Digital PCR Market Dynamics
Figure 18: Likert Scale
Figure 19: Impact Analysis of Market Drivers and Challenges on the Global Digital PCR Market
Figure 20: Share of Key Developments and Strategies, January 2019-January 2022
Figure 21: Share of Mergers and Acquisitions (by Company), January 2019-January 2022
Figure 22: Share of Synergistic Activities (by Company), January 2019-January 2022
Figure 23: Share of Product Launch and Approval Activities (by Company), January 2019-January 2022
Figure 24: Share of Expansion, Funding, and Other Activities (by Company), January 2019-January 2022
Figure 25: Market-Share Analysis for the Global Digital PCR Market, $Million, 2020 and 2021
Figure 26: Growth-Share Analysis of the Global Digital PCR Market (by Company), 2021
Figure 27: Growth-Share Analysis for Digital PCR Market (by Application Type), 2021
Figure 28: Supply Chain Analysis of the Global Digital PCR Market
Figure 29: Global Digital PCR Market (by Product)
Figure 30: Share of Global Digital PCR Market (by Product), $Million, 2021 and 2032
Figure 31: Digital PCR Systems Workflow
Figure 32: Global Digital PCR Market (Systems), $Million, 2021-2032
Figure 33: Sample Partitioning of Droplet Digital PCR System
Figure 34: Global Digital PCR Market (Droplet Digital PCR Systems), $Million, 2021-2032
Figure 35: Workflow of Chip-Based Digital PCR System
Figure 36: Global Digital PCR Market (Chip-Based Digital PCR Systems), $Million, 2021-2032
Figure 37: Global Digital PCR Market (Kits and Assays), $Million, 2021-2032
Figure 38: Global Digital PCR Market (Kits and Assays for Droplet Digital PCR Systems), $Million, 2021-2032
Figure 39: Global Digital PCR Market (Kits and Assays for Chip-Based Digital PCR Systems), $Million, 2021-2032
Figure 40: Global Digital PCR Market (Reagents and Consumables), $Million, 2021-2032
Figure 41: Global Digital PCR Market (Reagents and Consumables for Droplet Digital PCR Systems), $Million, 2021-2032
Figure 42: Global Digital PCR Market (Reagents and Consumables for Chip-Based Digital PCR), $Million, 2021-2032
Figure 43: Global Digital PCR Market (by Application Type)
Figure 44: Share of Global Digital PCR Market (by Application Type), $Million, 2021 and 2032
Figure 45: Estimated New Breast Cancer Cases among Female Population
Figure 46: Global Digital PCR Market (Oncology), $Million, 2021-2032
Figure 47: Global Digital PCR Market (Solid Tumor, by Oncology), $Million, 2021-2032
Figure 48: Global Digital PCR Market (Hematologic Malignancies, by Oncology), $Million, 2021-2032
Figure 49: Global Digital PCR Market (Infectious Diseases), $Million, 2021-2032
Figure 50: Distribution of Respiratory Infections
Figure 51: Global Digital PCR Market (Respiratory Infections, by Infectious Diseases), $Million, 2021-2032
Figure 52: Global Digital PCR Market (Gastrointestinal Infections, by Infectious Diseases), $Million, 2021-2032
Figure 53: Global Digital PCR Market (Other Infectious Diseases, by Infectious Diseases), $Million, 2021-2032
Figure 54: Global Burden of Rare Diseases
Figure 55: Global Digital PCR Market (Rare Diseases), $Million, 2021-2032
Figure 56: Global Digital PCR Market (Inherited Trait Type, by Rare Diseases), $Million, 2021-2032
Figure 57: Global Digital PCR Market (Acquired Trait Type, by Rare Diseases), $Million, 2021-2032
Figure 58: Global Digital PCR Market (Reproductive Genetics), $Million, 2021-2032
Figure 59: Global Digital PCR Market (Prenatal Diseases, by Reproductive Genetics), $Million, 2021-2032
Figure 60: Global Digital PCR Market (Postnatal Diseases, by Reproductive Genetics), $Million, 2021-2032
Figure 61: Global Digital PCR Market (Gene Expression), $Million, 2021-2032
Figure 62: Global Digital PCR Market (Other Applications), $Million, 2021-2032
Figure 63: Global Digital PCR Market (by End User)
Figure 64: Share of Global Digital PCR Market (by End User), $Million, 2021 and 2032
Figure 65: Global Digital PCR Market (Academic and Research Institutions), $Million, 2021-2032
Figure 66: Global Digital PCR Market (Hospitals and Clinics), $Million, 2021-2032
Figure 67: Global Digital PCR Market (Diagnostic Centers), $Million, 2021-2032
Figure 68: Global Digital PCR Market (Biopharmaceutical Companies), $Million, 2021-2032
Figure 69: Global Digital PCR Market Snapshot (by Region)
Figure 70: Global Digital PCR Market (by Region), $Million, 2021-2032
Figure 71: Share of Global Digital PCR Market (by Region), $Million, 2021 and 2032
Figure 72: North America Digital PCR Market, $Million, 2021-2032
Figure 73: Growth Potential Analysis (by Country), $Million, 2021-2032
Figure 74: U.S. Digital PCR Market, $Million, 2021-2032
Figure 75: U.S. Digital PCR Market (by End User), $Million, 2021-2032
Figure 76: Canada Digital PCR Market, $Million, 2021-2032
Figure 77: Canada Digital PCR Market (by End User), $Million, 2021-2032
Figure 78: Europe Digital PCR Market, $Million, 2021-2032
Figure 79: Growth Potential Analysis (by Country), $Million, 2021–2032
Figure 80: Germany Digital PCR Market, $Million, 2021-2032
Figure 81: Germany Digital PCR Market (by End User), $Million, 2021-2032
Figure 82: France Digital PCR Market, $Million, 2021-2032
Figure 83: France Digital PCR Market (by End User), $Million, 2021-2032
Figure 84: U.K. Digital PCR Market, $Million, 2021-2032
Figure 85: U.K. Digital PCR Market (by End User), $Million, 2021-2032
Figure 86: Italy Digital PCR Market, $Million, 2021-2032
Figure 87: Italy Digital PCR Market (by End User), $Million, 2021-2032
Figure 88: Spain Digital PCR Market, $Million, 2021-2032
Figure 89: Spain Digital PCR Market (by End User), $Million, 2021-2032
Figure 90: Rest-of-Europe Digital PCR Market, $Million, 2021-2032
Figure 91: Rest-of-Europe Digital PCR Market (by End User), $Million, 2021-2032
Figure 92: Asia-Pacific Digital PCR Market, $Million, 2021-2032
Figure 93: Growth Potential Analysis (by Country), $Million, 2021-2032
Figure 94: Japan Digital PCR Market, $Million, 2021-2032
Figure 95: Japan Digital PCR Market (by End User), $Million, 2021-2032
Figure 96: China Digital PCR Market, $Million, 2021-2032
Figure 97: China Digital PCR Market (by End User), $Million, 2021-2032
Figure 98: Australia Digital PCR Market, $Million, 2021-2032
Figure 99: Australia Digital PCR Market (by End User), $Million, 2021-2032
Figure 100: South Korea Digital PCR Market, $Million, 2021-2032
Figure 101: South Korea Digital PCR Market (by End User), $Million, 2021-2032
Figure 102: Rest-of-Asia-Pacific Digital PCR Market, $Million, 2021-2032
Figure 103: Rest-of-Asia-Pacific Digital PCR Market (by End User), $Million, 2021-2032
Figure 104: Latin America Digital PCR Market, $Million, 2021-2032
Figure 105: Growth Potential Analysis (by Country), $Million, 2021-2032
Figure 106: Brazil Digital PCR Market, $Million, 2021-2032
Figure 107: Brazil Digital PCR Market (by End User), $Million, 2021-2032
Figure 108: Mexico Digital PCR Market, $Million, 2021-2032
Figure 109: Mexico Digital PCR Market (by End User), $Million, 2021-2032
Figure 110: Rest-of-Latin America Digital PCR Market, $Million, 2021-2032
Figure 111: Rest-of-Latin America Digital PCR Market (by End User), $Million, 2021-2032
Figure 112: Rest-of-the-World Digital PCR Market, $Million, 2021-2032
Figure 113: Middle East Digital PCR Market, $Million, 2021-2032
Figure 114: K.S.A. Digital PCR Market, $Million, 2021-2032
Figure 115: Turkey Digital PCR Market, $Million, 2021-2032
Figure 116: Egypt Digital PCR Market, $Million, 2021-2032
Figure 117: Rest-of-Middle East Digital PCR Market, $Million, 2021-2032
Figure 118: Africa Digital PCR Market, $Million, 2021-2032
Figure 119: Total Number of Companies Profiled
Figure 120: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 121: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
Figure 122: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 123: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
Figure 124: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 125: Fluidigm Corporation: Product Portfolio
Figure 126: Fluidigm Corporation: Overall Financials, $Million, 2019-2021
Figure 127: Fluidigm Corporation: Revenue (by Region), $Million, 2019-2021
Figure 128: Fluidigm Corporation: R&D Expenditure, $Million, 2019-2021
Figure 129: F. Hoffmann-La Roche Ltd.: Product Portfolio
Figure 130: F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2019-2021
Figure 131: F. Hoffmann-La Roche Ltd.: Revenue (by Segment), $Million, 2019-2021
Figure 132: F. Hoffmann-La Roche Ltd.: Revenue (by Region), $Million, 2019-2021
Figure 133: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2019-2021
Figure 134: Merck KGaA: Product Portfolio
Figure 135: Merck KGaA: Overall Financials, $Million, 2019-2021
Figure 136: Merck KGaA: Revenue (by Segment), $Million, 2019-2021
Figure 137: Merck KGaA: Revenue (by Region), $Million, 2019-2021
Figure 138: Merck KGaA: R&D Expenditure, $Million, 2019-2021
Figure 139: QIAGEN N.V.: Product Profile
Figure 140: QIAGEN N.V.: Overall Financials, $Million, 2019-2021
Figure 141: QIAGEN N.V.: Revenue (by Segment), $Million, 2019-2021
Figure 142: QIAGEN N.V.: Revenue (by Region), $Million, 2019-2021
Figure 143: QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021
Figure 144: Thermo Fisher Scientific Inc.: Product Portfolio
Figure 145: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
Figure 146: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2019-2021
Figure 147: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021
Figure 148: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021
Figure 149: Genetron Holdings Limited: Product Portfolio
Figure 150: Genetron Holdings Limited: Overall Financials, $Million, 2019-2021
Figure 151: Genetron Holdings Limited: Revenue (by Segment), $Million, 2019-2021
Figure 152: Genetron Holdings Limited: R&D Expenditure, $Million, 2019-2021
Figure 153: JN Medsys: Product Portfolio
Figure 154: Stilla: Product Portfolio
Figure 155: Naveris, Inc.: Product Portfolio
Figure 156: SAGA Diagnostics: Product Portfolio
List of Tables
Table 1: Non-Invasive Prenatal Testing Performance by Digital PCR
Table 2: Advantages of Digital PCR over Conventional PCR
Table 3: Digital PCR Diagnostics Solutions Offered for COVID-19
Table 4: Registration Criteria for IVD Medical Devices as per the CFDA
Table 5: Different Technology-Based Products
Table 6: Different Application-Based Products
Table 7: Companies Providing Digital PCR Systems
Table 8: Companies Providing Droplet Digital PCR Systems
Table 9: Companies Providing Chip-Based Digital PCR Systems
Table 10: Companies Providing Kits and Assays for Digital PCR Systems
Table 11: Companies Providing Reagents and Consumables for Digital PCR Systems
Table 12: Hematologic Malignancies and Their Targets Using Droplet Digital PCR Systems
Table 13: North America: Market Dynamics
Table 14: Europe: Market Dynamics
Table 15: Asia-Pacific: Market Dynamics
Table 16: Latin America: Market Dynamics
Company Mentioned
Bio-Rad Laboratories, Inc.
Fluidigm Corporation
F. Hoffmann-La Roche Ltd.
Merck KGaA
QIAGEN N.V.
Thermo Fisher Scientific Inc.
Genetron Holdings Limited
JN Medsys
Stilla
Naveris, Inc.
SAGA Diagnostics
Reviews
There are no reviews yet.